SHUNHO STOCK(SZ:002565) Jin Rong Jie·2025-12-14 13:00Major Announcements - Shunhao Co., Ltd. faces potential delays and lower-than-expected commercialization benefits for its space data center project due to strong radiation and other factors [1] - Pudong Jinqiao's chairman Wang Ying has left the company due to a job transfer [1] Investment Projects - Jiaze New Energy plans to invest approximately 3.557 billion yuan in a green hydrogen and aviation fuel chemical co-production project in Jixi City, Heilongjiang Province [2] - Zoli Pharmaceutical intends to acquire a multi-trace element injection asset group for a total price of 356 million yuan [2] Regulatory Approvals - Jiankang Medical's U.S. subsidiary received pre-market notifications from the FDA for its four-in-one and three-in-one testing kits for respiratory viruses [3] - Saiyi Information has been approved to lead a national major science and technology project focused on intelligent manufacturing systems and robotics [4] - Jinpan Technology has received approval from the China Securities Regulatory Commission for issuing convertible bonds to unspecified investors [2] Corporate Actions - Hason Co., Ltd. is adjusting its plan to acquire assets, now focusing solely on acquiring a 45% stake in Suzhou Langkes [5] - Yipin Hong's U.S. subsidiary Arthrosi Therapeutics is set to be acquired by Sobi USA for a total of up to 950 million USD [5] - Zhonghuan Environmental plans to raise no more than 300 million yuan through a private placement to supplement working capital and repay loans [6] Clinical Trials and Approvals - Junshi Biosciences has received FDA approval for clinical trials of its JS212 drug for treating advanced solid tumors [7]